An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by researchers at the National Cancer Institute’s (NCI) Center for Cancer Research.
The Early Cancer Therapeutics Group at Mayo Clinic offers patients whose cancers haven’t responded to standard chemotherapy or other treatments the opportunity to join an early-phase clinical trial of a potential new treatment.
Keytruda (pembrolizumab) is an immunotherapy cancer treatment that stimulates the patient’s immune system to help fight certain types of cancers. Because cancer cells can use certain proteins, like the PD-1 protein, to shield themselves from detection, this enables cancer cells to grow and spread.
Opdivo (nivolumab) is an FDA- approved immunotherapy cancer drug treatment that is showing great promise for treating various types of cancer, including melanoma, lung cancer, kidney cancer and Hodgkin lymphoma. As a disease, cancer escapes the immune system by producing certain proteins that can hide it.
Dr. Jedd Wolchok, Chief, Melanoma and Immunotherapeutic Service, Memorial Sloan Kettering Cancer Center, with Alex Wagner, Senior Editor, The Atlantic, discuss the promise of immunotherapy in oncology and the search for answers in the treatment for cancer.
This animation created by Nature Reviews Cancer and Nature Reviews Immunology illustrates how tumor cells are sensed and destroyed by cells of the immune system and how tumors can evolve to evade immune-mediated elimination.